Britannia Life Sciences, Inc. (RLSC) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Negative results for the last 4 consecutive quarters

NET PROFIT(Q) At CAD -0.14 MM has Fallen at -203.69%
OPERATING CASH FLOW(Y) Lowest at CAD 1.11 MM
ROCE(HY) Lowest at -175.45%

Risky - Negative EBITDA

Mojo Parameters

Stock DNA

Industry

Other Agricultural Products

Market cap

CAD 15 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.80

Return on Equity

-48.16%

Price to Book

2.62

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

38.46%

6 Months

50.0%

1 Year

80.0%

2 Years

38.46%

3 Years

50.0%

4 Years

-52.63%

5 Years

350.0%

Britannia Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

41.83%

EBIT Growth (5y)

15.22%

EBIT to Interest (avg)

-1.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

4.92

Sales to Capital Employed (avg)

0.66

Tax Ratio

3.51%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.09%

ROE (avg)

4.44%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.76

EV to EBIT

10.85

EV to EBITDA

10.85

EV to Capital Employed

9.80

EV to Sales

1.93

PEG Ratio

Dividend Yield

ROCE (Latest)

17.97%

ROE (Latest)

-48.16%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -88.89% vs -10.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -800.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "1.80",
          "chgp": "-88.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "0.20",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,134.40%",
          "val2": "92.80%",
          "chgp": "-222.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -20.00% vs -92.19% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 24.59% vs -205.17% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-6.80",
          "chgp": "67.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "1.90",
          "chgp": "-84.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.60",
          "val2": "-6.10",
          "chgp": "24.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,999.70%",
          "val2": "-13,201.30%",
          "chgp": "720.16%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.20

1.80

-88.89%

Operating Profit (PBDIT) excl Other Income

-0.30

0.20

-250.00%

Interest

0.00

0.30

-100.00%

Exceptional Items

0.10

0.00

Consolidate Net Profit

-0.70

Operating Profit Margin (Excl OI)

-2,134.40%

92.80%

-222.72%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -88.89% vs -10.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs -800.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.40

0.50

-20.00%

Operating Profit (PBDIT) excl Other Income

-2.20

-6.80

67.65%

Interest

0.10

Exceptional Items

0.30

1.90

-84.21%

Consolidate Net Profit

-4.60

-6.10

24.59%

Operating Profit Margin (Excl OI)

-5,999.70%

-13,201.30%

720.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -20.00% vs -92.19% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 24.59% vs -205.17% in Mar 2024

All Annual Results

Company CV

About Britannia Life Sciences, Inc.

Britannia Life Sciences, Inc.

Other Agricultural Products

Rise Life Science Corp, formerly Luminor Medical Technologies Inc, is a Canada-based company engaged in alternative medicine sector. The Company is focused on developing and evolving medical cannabis-based formulations to create health and well being products. The Company develops cannabis consumer products for both medical and adult use markets around the world, to address adult sexual health and wellness for both men and women. All products are based on patent pending formulations and processes to produce specific targeted effects.

Company Coordinates

Company Details

145 King St W Suite 210 , TORONTO ON : M5H 1J8

Tel: 1 416 3020779

http://riselifescience.com/

Registrar Details